Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

C. Byrd, John

doi:10.1182/blood-2002-04-1258

Public

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)

Published in Blood • Jul 5, 2002

Authors:

John C. Byrd

Abstract

Recent studies have suggested that rituximab has clinical activity and modulates antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia (CLL). We performed a randomized phase 2 study to determine the efficacy, safety, and optimal administration schedule of rituximab w...

Subject

Fludarabine

Chronic lymphocytic leukemia

Rituximab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!